This site is intended only for healthcare professionals residing in Malaysia

Search

Menu

Close

Log Out Our medicinesTherapy AreaExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer medical information

Sexually Transmitted Infections  |  Chancroid/Genital Ulcers Men

Chancroid/Genital Ulcers Men

Administration

Guidelines

Epidemiology

Tab Number 5

Efficacy

Administration

Adults1

Single 1g dose

  • ZITHROMAX should be given as a single daily dose1–3
  • ZITHROMAX tablets and suspension can be taken with or without food1
  • ZITHROMAX capsules should be taken at least 1 hour before or 2 hours after food2
Renal Impairment2,3

No dose adjustment is necessary in patients with mild to moderate renal impairment (glomerular filtration rate [GFR] of 10–80 mL/min). Caution should be exercised when ZITHROMAX is administered to patients with severe renal impairment (GFR <10 mL/min)

Hepatic Impairment2,3

Since azithromycin is metabolized in the liver and excreted in the bile, the drug should not be given to patients suffering from severe liver disease. No studies have been conducted regarding treatment of such patients with azithromycin

This is the Second tab of content! Lorem ipsum ap dolor sit amet consectetur adipisicing elit.

GuidelinesAzithromycin: recommended in infection control guidelinesAzithromycin is recommended as a treatment option in the following guidelines: Management of Chancroid4

European Guidelines 2017

 View guidelines Loading Sexually Transmitted Diseases Treatment Guidelines5

Centers for Disease Control and Prevention (CDC) 2021

 View guidelines Loading

This is the Third tab of content! Lorem ipsum ap dolor sit amet consectetur adipisicing elit.

This is the Fourth tab of content! Lorem ipsum ap dolor sit amet consectetur adipisicing elit.

TitleZITHROMAX is contraindicated in patients with a known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic, or to any of the excipients.2
The most recent local resistance data available must always take precedence when selecting antimicrobial therapy; in settings where local resistance data are not available, national and international guidelines can help inform antimicrobial choice.
As with any antibiotic preparation, observation for signs of superinfection with non-susceptible organisms including fungi is recommended. Clostridium difficile associated diarrhea has been reported with azithromycin, and may range in severity from mild diarrhea to fatal colitis.2
The prevalence of acquired resistance to azithromycin may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. Expert advice should be sought when the local prevalence of resistance is such that the utility of azithromycin in at least some types of infections is questionable.2
Caution should be exercised when ZITHROMAX is administered to patients with severe renal impairment (GFR <10 mL/min).2You might also be interested in...Sexually Transmitted Infections Infections by Chlamydia trachomatis Find out more LoadingSexually Transmitted Infections Infections by Neisseria gonorrhoeae Find out more LoadingResources ZITHROMAX® Mode of Action Find out more LoadingReferencesZITHROMAX label, Reference ID: 3263750. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050710s039,050711s036,050784s023lbl.pdf. Accessed June 2023.ZITHROMAX 250 mg Capsules Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/1073/smpc. Accessed June 2023.ZITHROMAX Powder for Oral Suspension Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/3006/smpc. Accessed June 2023.Lautenschlager S, et al. Int J STD AIDS. 2017;28(4):324–9.Workowski KA, et al. MMWR Recomm Rep. 2021;70(4):1–192.Martin DH, et al. Clin Infect Dis. 1995;21:409–14.
Sexually Transmitted Infections ZITHROMAX® Safety Information Find out more Loading
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for healthcare professionals residing in Malaysia. If you are a member of public wishing to access information on a specific medicine, please consult with your doctor.

 

This website is brought to you by
Pfizer (Malaysia) Sdn Bhd 197801003134
(40131-T)
Level 10 & 11, Wisma Averis (Tower 2),
Bangsar South, No. 8, Jalan Kerinchi, 
59200 Kuala Lumpur, Malaysia.
Tel: 603-2281 6000 
Fax: 603-2281 6388 
 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

PP-ZIT-MYS-0243-28FEB2024
You are now leaving the PfizerPro Malaysia website
​
You are now being directed to a third-party website. It is clarified that Pfizer will not be collecting, storing, or accessing any personal information shared by you on the third-party website and Pfizer's Privacy Policy will not apply. Pfizer does not review or control or endorse the content of the third-party website and shall have no liability / assumes no responsibility for any issues arising out of you accessing the third-party website, accuracy of the information, practices, and standards of the third-party website. You will be bound by the Privacy Policy and Terms of Use of the third-party website and be solely responsible for your interactions with that website.
 
     PP-UNP-MYS-0077 - 10FEB2023